远大医药在心脑血管精准介入诊疗领域同样积极拓展全球布局，公司目前已和美国、加拿大、德国、意 大利、瑞士等多国临床中心或者研发平台进行技术合作，并已实现"无源+有源"创新器械平台的全面建 设。未来，随着公司"Go Global"战略的持续推进，远大医药有望将该板块打造为全球领先的"心脑血管 精准介入诊疗平台"，促进公司价值的进一步提升。 据悉，远大医药在高端医疗器械领域已深耕多年，公司秉承"精准治疗"的治疗理念，围绕通路管理、结 构性心脏病及心衰三个方向进行全方位布局，搭建高端医疗器械产品集群。目前公司该板块已布局超过 30款产品，其中通路管理方向已有23款在中国获批上市，结构性心脏病方向已有1款产品在中国获批上 市，其他产品也在积极推进中国临床注册工作，未来有望实现创新产品分阶段分梯次上市，带动公司该 板块业务稳定增长。 中证报中证网讯(记者傅苏颖)9月11日，中国证券报记者从远大医药获悉，公司颅内动脉瘤辅助栓塞支 架蓝鲸TM近日在国内获批上市，为我国颅内动脉瘤治疗带来全新的治疗选择。 ...

Core Viewpoint - The company, Yuan Da Pharmaceutical, has made significant breakthroughs in nuclear medicine for tumor diagnosis and treatment, as well as in sepsis, leading to a surge in its stock price, which reached a historical high of 9.20 HKD, an increase of over 130% from its low this year [1] Group 1: Product Launch and Clinical Application - The NeoNova transcatheter mitral valve repair system, developed independently in China, has officially commenced its first commercial implantations across multiple centers nationwide [1][3] - NeoNova offers a minimally invasive solution for patients with mitral valve regurgitation, enhancing heart function while reducing surgical trauma and recovery time [3] - The product has been successfully implanted by several top cardiac centers, showcasing its clinical advantages and effectiveness in treating severe mitral valve regurgitation [5][12] Group 2: Clinical Advantages and Innovations - NeoNova features several innovative designs, including a unique "one-line" structure to minimize chordae tendineae entanglement, an "elastic self-locking" mechanism to protect valve leaflets, and a small radius curvature to lower puncture height requirements [6][8] - Clinical trials have demonstrated significant improvements in patients' conditions, with reductions in regurgitation severity and cross-valve pressure [10][12] - The product's design allows for efficient and safe procedures, with some surgeries completed in as little as 35 minutes, highlighting its operational convenience [8][12] Group 3: Strategic Development and Future Outlook - The company is committed to advancing high-end medical device research and aims to establish a leading global platform for precise interventional diagnosis and treatment in cardiovascular and cerebrovascular fields [15][18] - Yuan Da Pharmaceutical has a robust pipeline with 27 products in development, including five innovative products, and is actively pursuing regulatory approvals for various devices [15][18] - The company emphasizes the importance of innovation and advanced technology, planning to increase investments in global product development to enhance its product offerings and market presence [18]